Systematic identification of genomic markers of drug sensitivity in cancer cells

Cited by (1,004)

Items 601–700 of 1,004

1. A mechanistic pan-cancer pathway model informed by multi-omics data interprets stochastic cell fate responses to drugs and mitogens
   Bouhaddou, Mehdi, Barrette, Anne Marie, Stern, Alan D., Koch, Rick J., DiStefano, Matthew S., Riesel, Eric A., Santos, Luis C., Tan, Annie L., Mertz, Alex E., Birtwistle, Marc R. · 2018 · PLOS Computational Biology
2. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer.
   Peter Stephen Savas, Brett G.M. Hughes, Benjamin Solomon · 2013 · Europe PMC (PubMed Central)
3. Predicting Anticancer Drug Response With Deep Learning Constrained by Signaling Pathways
   Heming Zhang, Yixin Chen, Fuhai Li · 2021 · Frontiers in Bioinformatics
4. A landscape of response to drug combinations in non-small cell lung cancer
   Nishanth Ulhas Nair, Patricia Greninger, Xiaohu Zhang, Adam A. Friedman, Arnaud Amzallag, Eliane Cortez, Avinash D Sahu, Joo Sang Lee, Anahita Dastur, Regina K. Egan et al. · 2023 · Nature Communications
5. A deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitors
   Sungjoon Park, Erica Silva, Akshat Singhal, Marcus R. Kelly, Kate S. Licon, Isabella Panagiotou, Catalina Fogg, Samson H. Fong, John J. Y. Lee, Xiaoyu Zhao et al. · 2024 · Nature Cancer
6. Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity
   Fabrício Garmus Sousa, Renata Matuo, Sai-Wen Tang, Vinodh N. Rajapakse, Augustin Luna, Chris Sander, Sudhir Varma, Paul H. G. Simon, James H. Doroshow, William C. Reinhold et al. · 2015 · DNA repair
7. Adaptive Resistance to an Inhibitor of Chromosomal Instability in Human Cancer Cells
   Bernardo Orr, Lama Talje, Zhexian Liu, Benjamin H. B. Kwok, Duane A. Compton · 2016 · Cell Reports
8. Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
   S.W. Ember, Que T. Lambert, Norbert Berndt, Steven Gunawan, Muhammad Ayaz, Marilena Tauro, Jin‐Yi Zhu, Paula J. Cranfill, Patricia Greninger, Conor C. Lynch et al. · 2017 · Molecular Cancer Therapeutics
9. Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies
   Peng Jiang, Winston Lee, Xujuan Li, Carl Johnson, Jun S. Liu, Myles A Brown, Jon Christopher Aster, X. Shirley Liu · 2018 · Cell Systems
10. Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer
    Xiaoyu Liu, Changyu Li, Junhao Li, Tianzhu Yu, Guofeng Zhou, Jiemin Cheng, Guoping Li, Yang Zhou, Wenhui Lou, Xiaolin Wang et al. · 2018 · Journal of Cancer
11. Evolving neoantigen profiles in colorectal cancers with DNA repair defects
    Giuseppe Rospo, Annalisa Lorenzato, Nabil Amirouchene-Angelozzi, Alessandro Magrì, Carlotta Cancelliere, Giorgio Corti, Carola Negrino, Vito Amodio, Monica Montone, Alice Bartolini et al. · 2019 · Genome Medicine
12. Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors
    Simon April-Monn, Tabea Wiedmer, Magdalena Skowronska, Renaud Maire, Marco Schiavo Lena, Mafalda Trippel, Annunziata Di Domenico, Francesca Muffatti, Valentina Andreasi, Gabriele Capurso et al. · 2020 · Neuroendocrinology
13. Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2
    Liam Baird, Takafumi Suzuki, Yushi Takahashi, Eiji Hishinuma, Daisuke Saigusa, Masayuki P. Yamamoto · 2020 · Molecular and Cellular Biology
14. A Systematic Review of Applications of Machine Learning in Cancer Prediction and Diagnosis
    Aman Sharma, Rinkle Rani · 2021 · Archives of Computational Methods in Engineering
15. Glutamine synthetase licenses APC/C-mediated mitotic progression to drive cell growth
    Jiang‐Sha Zhao, Shuo Shi, Hai-Yan Qu, Zuzana Keckesova, Zi-Jian Cao, Lixian Yang, Xiaofu Yu, Limin Feng, Zhong Shi, Joanna Krakowiak et al. · 2022 · Nature Metabolism
16. Linking Tumor Mutations to Drug Responses via a Quantitative Chemical–Genetic Interaction Map
    Maria M. Martins, Alicia Yiran Zhou, Alexandra N. Corella, Dai Horiuchi, Christina S. F. Yau, Taha Rakhshandehroo, John Dozier Gordan, Rebecca S. Levin, Jeffrey R. Johnson, John Jascur et al. · 2014 · Cancer Discovery
17. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p
    Christina G. Towers, Anna L. Guarnieri, Douglas Scott Micalizzi, Joshua Chuck Harrell, Austin E. Gillen, Jihye Kim, Chu-An Wang, Michael U.J. Oliphant, David J. Drasin, Michelle A. Guney et al. · 2015 · Nature Communications
18. Web-based drug repurposing tools: a survey
    Elizabeth Sam, Prashanth Athri · 2017 · Briefings in Bioinformatics
19. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications
    Shuyu Dan Li, Meng Ma, Hui Li, Aneta Waluszko, Tatyana Sidorenko, Eric E. Schadt, David Yu Zhang, Rong Chen, Fei Ye · 2017 · Genome Medicine
20. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
    Varun V. Prabhu, Neel S. Madhukar, Coryandar M. Gilvary, Christina Leah B. Kline, Sophie Oster, Wafik S. El‐Deiry, Olivier Elemento, Faye C. Doherty, Alexander VanEngelenburg, Jessica Durrant et al. · 2018 · Clinical Cancer Research
21. Comprehensive anticancer drug response prediction based on a simple cell line-drug complex network model
    Wei Gou Dong, Chuanying Liu, Xiaoqi Zheng, Yushuang Li · 2019 · BMC Bioinformatics
22. Representation of molecules for drug response prediction
    Xin An, Xi Chen, Daiyao Yi, Hongyang Li, Yuanfang Guan · 2021 · Briefings in Bioinformatics
23. Preclinical models in head and neck squamous cell carcinoma
    Patricia Cháves, María Garrido, Javier Oliver, Elísabeth Pérez-Ruiz, Isabel Barragán, Antonio Rueda‐Domínguez · 2023 · British Journal of Cancer
24. Resolving cancer–stroma interfacial signalling and interventions with micropatterned tumour–stromal assays
    Keyue Shen, Samantha O. Luk, Daniel F. Hicks, Jessica S. Elman, Stefan Bohr, Yoshiko Iwamoto, Ryan M. Murray, Kristen C. Peña, Fangjing Wang, Erkin Şeker et al. · 2014 · Nature Communications
25. CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery
    Ji Luo · 2016 · Trends in cancer
26. Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies
    Nikita V. Pozdeyev, Minjae Yoo, Ryan Mackie, Rebecca E. Schweppe, Aik Choon Tan, Bryan R. Haugen · 2016 · Oncotarget
27. Endometrial Carcinoma: Specific Targeted Pathways
    Núria Eritja, Andrée Yeramian, Bo‐Juen Chen, David Llobet‐Navàs, Eugenia Ortega, Eva Colás, Miguel Abal, Xavier Dolcet, Jaume Reventós, Xavier Matías‐Guiu · 2016 · Advances in experimental medicine and biology
28. Suppression of 19S proteasome subunits marks emergence of an altered cell state in diverse cancers
    Peter Tsvetkov, Ethan S. Sokol, Dexter X. Jin, Zarina Brune, Prathapan Thiru, Mahmoud Ghandi, Levi A. Garraway, Piyush B. Gupta, Sandro Santagata, Luke J. Whitesell et al. · 2016 · Proceedings of the National Academy of Sciences
29. Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
    Robert Campbell, Geoffrey Chong, Eliza Anne Hawkes · 2018 · Journal of Clinical Medicine
30. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors
    Garrett W. Rhyasen, Yi Yao, Jingwen Zhang, Austin M. Dulak, Lillian Castriotta, Kelly Jacques, Wei Zhao, Farzin Gharahdaghi, Maureen Mertens Hattersley, Paul D. Lyne et al. · 2018 · PLoS ONE
31. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma
    Lijun Cheng, Pankita H. Pandya, Enze Liu, Pooja Chandra, Limei Wang, Mary Ellen Murray, Jacquelyn Carter, Michael J. Ferguson, Mohammad Reza Saadatzadeh, Khadijeh Bijangi‐Vishehsaraei et al. · 2019 · BMC Medical Genomics
32. The Tumor Macroenvironment
    Melanie R. Rutkowski, Nikolaos Svoronos, Alfredo Perales‐Puchalt, Jose Ramon Conejo-Garcia · 2015 · Advances in cancer research
33. Analysis and modeling of cancer drug responses using cell cycle phase-specific rate effects
    Sean M. Gross, Farnaz Mohammadi, Crystal Sanchez-Aguila, Paulina J. Zhan, Tiera A. Liby, Mark A. Dane, Aaron S. Meyer, Laura M. Heiser · 2023 · Nature Communications
34. Integrated omics landscape of hepatocellular carcinoma suggests proteomic subtypes for precision therapy
    Xiaohua Xing, En Hu, Jiahe Ouyang, Xianyu Zhong, Fei Wang, Kaixin Liu, Linsheng Cai, Yang Zhou, Yingchao Wang, Geng Chen et al. · 2023 · Cell Reports Medicine
35. Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3
    Chu-An Wang, Joshua Chuck Harrell, Ritsuko Iwanaga, Paul Jedlicka, Heide L. Ford · 2014 · Breast Cancer Research
36. Accurate Models for P-gp Drug Recognition Induced from a Cancer Cell Line Cytotoxicity Screen
    Jurica Levatić, Jasna Ćurak, Marijeta Kralj, Tomislav Šmuc, Maja Osmak, Fran Supek · 2013 · Journal of Medicinal Chemistry
37. Potential approaches to the treatment of Ewing's sarcoma
    Hongjiu Yu, Yonggui Ge, Lianying Guo, Lin Huang · 2016 · Oncotarget
38. Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
    Banu Eskiocak, Elizabeth A. McMillan, Saurabh Mendiratta, Rahul Krishna Kollipara, Hailei Zhang, Caroline G. Humphries, Changguang Wang, José García‐Rodríguez, Ming Lei Ding, Aubhishek Zaman et al. · 2017 · Cancer Discovery
39. RAS–MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma
    Thomas F. Eleveld, Linda G. Schild, Jan Köster, Danny A. Zwijnenburg, Lindy K. Alles, Marli E. Ebus, Richard Volckmann, Godelieve A. Tijtgat, Peter V. Sluis, Rogier Versteeg et al. · 2018 · Cancer Research
40. Automated Tracking of Nanoparticle-labeled Melanoma Cells Improves the Predictive Power of a Brain Metastasis Model
    Terje Sundstrøm, Inderjit Daphu, INGVILD HAUKAAS WENDELBO, Erlend Hodneland, Arvid Lundervold, Heike Immervoll, Kai Ove Skaftnesmo, Michal Babič, Pavla Jendelová, Eva Syková et al. · 2013 · Cancer Research
41. DNA-Guided Precision Medicine for Cancer: A Case of Irrational Exuberance?
    Emile E. Voest, René Bernards · 2016 · Cancer Discovery
42. Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets
    Ellinor Andersson, Yvonne Arvidsson, Christina Swärd, Tobias Hofving, Bo Wängberg, Erik Kristiansson, Ola Nilsson · 2016 · Modern Pathology
43. Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma
    Johannes Brägelmann, Marcel Andre Dammert, Felix Dietlein, Johannes M. Heuckmann, Axel Choidas, Stefanie Böhm, André Richters, Debjit Basu, Verena Tischler, Carina Lorenz et al. · 2017 · Cell Reports
44. The germline genetic component of drug sensitivity in cancer cell lines
    Michael P. Menden, Francesco Paolo Casale, Johannes Stephan, Graham R. Bignell, Francesco Iorio, Ultan McDermott, Mathew J. Garnett, Julio Sáez-Rodríguez, Oliver Stegle · 2018 · Nature Communications
45. Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer
    In‐Kyu Kim, Justine N. McCutcheon, Guanhua Rao, Stephen V. Liu, Yves G. Pommier, Marcin Tomasz Skrzypski, Yu-Wen Zhang, Giuseppe Giaccone · 2018 · Oncogene
46. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies
    Zhiwei Liu, Yingluo Liu, Lili Qian, Shangwen Jiang, Xiameng Gai, Shu Ye, Yuehong Chen, Xiaomin Wang, Linhui Zhai, Jun Qiang Xu et al. · 2021 · Molecular Cell
47. DeepProfile: Deep learning of cancer molecular profiles for precision medicine
    Ayse Berceste Dincer, Safiye Celik, Naozumi Hiranuma, Su‐In Lee · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
48. Graph Transformer for Drug Response Prediction
    Thang Chu, Thuy Trang Nguyen, Bùi Dương Hải, Quang Huy Nguyen, Tuan Nguyen · 2022 · IEEE Transactions on Computational Biology and Bioinformatics
49. Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib
    Бин Ли, Hyunjin Shin, Georgy Gulbekyan, Olga Pustovalova, Yuri Nikolsky, Andrew J. Hope, Marina Bessarabova, Matthew C. Schu, Elona Kolpakova-Hart, David Merberg et al. · 2015 · PLoS ONE
50. Oncogenes in melanoma: An update
    Manfred Kunz · 2014 · European Journal of Cell Biology
51. FBXW7 Mediates Chemotherapeutic Sensitivity and Prognosis in NSCLCs
    Takehiko Yokobori, Yozo Yokoyama, Akira Mogi, Hideki Endoh, Bolag Altan, Takayuki Kosaka, Ei Yamaki, Toshiki Yajima, Kenji Tomizawa, Yoko Azuma et al. · 2013 · Molecular Cancer Research
52. Synthetic Lethality in Cancer Therapeutics
    Roderick L. Beijersbergen, Lodewyk F.A. Wessels, René Bernards · 2016 · Annual Review of Cancer Biology
53. Characterization of Cell-Type-Specific Drug Transport and Resistance of Breast Cancers Using Tumor-Microenvironment-on-Chip
    Kyeonggon Shin, Brett S. Klosterhoff, Bumsoo Han · 2016 · Molecular Pharmaceutics
54. Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors
    Lim, Joline, Tan, David S. P. · 2017 · Cancers
55. Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy
    Tracy L. Rose, David D. Chism, Ajjai Shivaram Alva, Allison Mary Deal, Susan J. Maygarden, Young E. Whang, Jordan Kardos, Anthony Drier, Ethan Basch, Paul Alphonso Godley et al. · 2018 · British Journal of Cancer
56. Development of Prostate Cancer Organoid Culture Models in Basic Medicine and Translational Research
    Mohamed Elbadawy, Amira Abugomaa, Hideyuki Yamawaki, Tatsuya Usui, Kazuaki Sasaki · 2020 · Cancers
57. Confocal SERS Mapping of Glycan Expression for the Identification of Cancerous Cells
    Derek Craig, Sarah McAughtrie, Jonathan Simpson, Corinna McCraw, Karen Faulds, Duncan Graham · 2014 · Analytical Chemistry
58. Epithelial–Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor–Mediated Apoptosis in Non–Small Cell Lung Cancer
    Renata Ferrarotto, Ruchitha Goonatilake, Suk Young Yoo, Pan Tong, Uma P. Giri, Shaohua Peng, John Dorrance Minna, Luc Girard, Yuehong Wang, Liguang Wang et al. · 2015 · Clinical Cancer Research
59. Prolyl-isomerase Pin1 controls Notch3 protein expression and regulates T-ALL progression
    Giulia Franciosa, Giulia Diluvio, Francesca Del Gaudio, Maria Valeria Giuli, Rocco Palermo, Paola Grazioli, Antonio Francesco Campese, Claudio Talora, Diana Bellavia, Giulia d’Amati et al. · 2016 · Oncogene
60. Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer
    Vikram B. Wali, Casey G. Langdon, Matthew A. Held, James T. Platt, Gauri Anand Patwardhan, Anton Mikhailovich Safonov, Bilge Aktaş, Lajos Pusztai, David F. Stern, Christos Hatzis · 2016 · Cancer Research
61. Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States
    Jong Wook Kim, Omar O. Abudayyeh, Huwate Yeerna, Chen‐Hsiang Yeang, Michelle L. Stewart, Russell William Jenkins, Shunsuke Kitajima, David Joseph Konieczkowski, Kate Medetgul-Ernar, Taylor B. Cavazos et al. · 2017 · Cell Systems
62. Fusion genes: A promising tool combating against cancer
    Xiaofeng Dai, Rutaganda Theobard, Hongye Cheng, Mengtao Xing, Jianying Zhang · 2018 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
63. Prediction of drug response in multilayer networks based on fusion of multiomics data
    Liang Yu, Dandan Zhou, Lin Gao, Yunhong Zha · 2020 · Methods
64. Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11
    Ukhyun Jo, Yasuhisa Murai, Naoko Takebe, Anish Thomas, Yves G. Pommier · 2021 · Cancers
65. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response
    Xiaohui Shen, Yuchen Zhang, Zhuoqing Xu, Han Gao, Wenqing Feng, Wenchang Li, Yiming Miao, Zifeng Xu, Yaping Zong, Jingkun Zhao et al. · 2022 · Cell Death and Disease
66. Human aneuploid cells depend on the RAF/MEK/ERK pathway for overcoming increased DNA damage
    Johanna Zerbib, Marica Rosaria Ippolito, Yonatan Eliezer, Giuseppina De Feudis, Eli Reuveni, Anouk Savir Kadmon, Sara Martin, Sonia Viganò, Gil Leor, James Berstler et al. · 2024 · Nature Communications
67. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
    Britta Julia Vormoor, Nicola J. Curtin · 2014 · Current Opinion in Oncology
68. BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
    M. Ranzani, C. Alifrangis, D. Perna, K. Dutton-Regester, A. Pritchard, Kim Wong, Mamunur Rashid, C. D. Robles-Espinoza, N. Hayward, U. McDermott et al. · 2014 · Pigment Cell & Melanoma Research
69. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP
    Avital Lev, Amriti R. Lulla, Jessica Wagner, Marie D. Ralff, Joshua B. Kiehl, Yan Zhou, Cyril H. Benes, Varun V. Prabhu, Wolfgang Oster, Igor A. Astsaturov et al. · 2017 · Oncotarget
70. Emerging Opportunities for Target Discovery in Rare Cancers
    Tanaz Sharifnia, Andrew Lee Hong, Corrie Painter, Jesse S. Boehm · 2017 · Cell chemical biology
71. Molecular characterization and integrative genomic analysis of a panel of newly established penile cancer cell lines
    Qiang-Hua Zhou, Chuang-Zhong Deng, Zai-Shang Li, Jie-Ping Chen, Kai Yao, Kang-bo Huang, Ting‐Yu Liu, Zhuowei Liu, Zike Qin, Fangjian Zhou et al. · 2018 · Cell Death and Disease
72. Predict drug sensitivity of cancer cells with pathway activity inference
    Xuewei Wang, Zhifu Sun, Michael T. Zimmermann, Andrej E. Bugrim, Jean‐Pierre Kocher · 2019 · BMC Medical Genomics
73. Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
    Duran-Frigola, Miquel, Cigler, Marko, Winter, Georg E. · 2023 · Journal of the American Chemical Society
74. Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting
    Alice Bradbury, Rachel Louise O'Donnell, Yvette Drew, Nicola J. Curtin, Sweta Sharma Saha · 2020 · Cancers
75. Explainable artificial intelligence for precision medicine in acute myeloid leukemia
    Marian Gimeno, Edurne San José‐Eneriz, Sara Villar, Xabier Agirre, Felipe Prósper, Angel Rubio, Fernando Carazo · 2022 · Frontiers in Immunology
76. Next generation organoid engineering to replace animals in cancer drug testing
    Sean Hockney, Jessica Parker, Jasmin E. Turner, Xanthea Todd, Stephen M. Todryk, Roben G. Gieling, Gerrit Hilgen, Davina C M Simoes, Deepali Pal · 2023 · Biochemical Pharmacology
77. LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation
    Katerina Mardilovich, Mark D. Baugh, Diane Crighton, Dominika Kowalczyk, Mads Gabrielsen, June Munro, Daniel R. Croft, Filipe Calheiros Lourenço, Daniel T. James, Gabriella Kalna et al. · 2015 · Oncotarget
78. Prospects and challenges for the development of new therapies for Ewing sarcoma
    Patrick Joseph Grohar, Lee J. Helman · 2012 · Pharmacology & Therapeutics
79. Modulators of Sensitivity and Resistance to Inhibition of PI3K Identified in a Pharmacogenomic Screen of the NCI-60 Human Tumor Cell Line Collection
    Kevin A. Kwei, Joffre B. Baker, Robert J. Pelham · 2012 · PLoS ONE
80. Recent advances in targeted therapy for Ewing sarcoma
    Kathleen I. Pishas, Stephen L. Lessnick · 2016 · F1000Research
81. Network dynamics-based cancer panel stratification for systemic prediction of anticancer drug response
    Minsoo Choi, Jue Shi, Yanting Zhu, Ruizhen Yang, Kwang‐Hyun Cho · 2017 · Nature Communications
82. Current questions in bone sarcomas
    Sandra J. Strauss, Jeremy Whelan · 2018 · Current Opinion in Oncology
83. Computational identification of multi-omic correlates of anticancer therapeutic response
    Stetson, Lindsay C, Pearl, Taylor, Chen, Yanwen, Barnholtz-Sloan, Jill S · 2014 · BMC Genomics
84. Precision Medicine in Oncology: In Vitro Drug Sensitivity and Resistance Test (DSRT) for Selection of Personalized Anticancer Therapy
    Anna A. Popova, Pavel A. Levkin · 2020 · Advanced Therapeutics
85. Graph Convolutional Network for Drug Response Prediction Using Gene Expression Data
    Seonghun Kim, Seockhun Bae, Yinhua Piao, Kyuri Jo · 2021 · Mathematics
86. NOTCH1 activation in breast cancer confers sensitivity to inhibition of SUMOylation
    Marco P. Licciardello, Markus K. Müllner, Gerhard Dürnberger, Claudia Kerzendorfer, Bernd Boidol, Claudia Jessen‐Trefzer, Sara Sdelci, Tobias Berg, Thomas Penz, Michael K. Schuster et al. · 2014 · Oncogene
87. Predictive biomarkers in precision medicine and drug development against lung cancer
    Bingliang Fang, Reza John Mehran, John Victor Heymach, Stephen G. Swisher · 2015 · 癌症：英文版
88. Methylseleninic acid promotes antitumour effects via nuclear FOXO3a translocation through Akt inhibition
    Míriam Tarrado‐Castellarnau, Roldán Cortés, Míriam Zanuy, Josep Tarragó‐Celada, Ibrahim H. Polat, Richard Hill, Teresa W.‐M. Fan, Wolfgang Link, Marta Cascante · 2015 · Pharmacological Research
89. Public data and open source tools for multi-assay genomic investigation of disease
    Lavanya Kannan, Marcel Ramos, Angela Re, Nehmé El-Hachem, Zhaleh Safikhani, Deena M.A. Gendoo, Sean R. Davis, David Gómez-Cabrero, Robert Castelo, Kasper D. Hansen et al. · 2015 · Briefings in Bioinformatics
90. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B
    Daniel C. Kirouac, Jinyan Du, Johanna Lahdenranta, Matthew David Onsum, Ulrik B. Nielsen, Birgit Schoeberl, Charlotte Fenton McDonagh · 2016 · PLoS Computational Biology
91. Inhibition of Lysyl Oxidases Improves Drug Diffusion and Increases Efficacy of Cytotoxic Treatment in 3D Tumor Models
    Friedrich Schütze, Florian Roehrig, Sandra Vorlová, Sabine Gätzner, Anja Kühn, Süleyman Ergün, Erik Henke · 2015 · Scientific Reports
92. Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity
    Pingping Fang, Cristabelle De Souza, Kay T. Minn, JEREMY R. CHIEN · 2019 · Communications Biology
93. Multifunctional Near-Infrared Fluorescent Probes with Different Ring-Structure Trigger Groups for Cell Health Monitoring and In Vivo Esterase Activity Detection
    Jiemin Wang, Zhidong Teng, Liang Zhang, Yuexia Yang, Jing Qian, Ting Cao, Yuping Cao, Wenwu Qin, Yun Liu, Huichen Guo · 2020 · ACS Sensors
94. DrBioRight 2.0: an LLM-powered bioinformatics chatbot for large-scale cancer functional proteomics analysis
    Wei Liu, Jun Li, Yitao Tang, Yining Zhao, Chaozhong Liu, Meiyi Song, Zhenlin Ju, Shwetha V. Kumar, Yiling Lu, Rehan Akbani et al. · 2025 · Nature Communications
95. Collections of Simultaneously Altered Genes as Biomarkers of Cancer Cell Drug Response
    David L. Masica, Rachel Karchin · 2013 · Cancer Research
96. Big Data for Precision Medicine
    Daniel Richard Leff, Guang‐Zhong Yang · 2015 · Engineering
97. Choosing wisely – Preclinical test models in the era of precision medicine
    Konrad Friedrich Klinghammer, Wolfgang Walther, Jens Hoffmann · 2017 · Cancer Treatment Reviews
98. Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors
    Nohemy Echeverry, Gabriela Ziltener, Dario Barbone, Walter Weder, Rolf Arno Stahel, V. Courtney Broaddus, Emanuela Felley‐Bosco · 2015 · Cell Death and Disease
99. Transcriptionally active enhancers in human cancer cells
    Katja Lidschreiber, Lisa Anna Jung, Henrik von der Emde, Kashyap Dave, Jussi Taipale, Patrick Cramer, Michael Lidschreiber · 2021 · Molecular Systems Biology
100. Differential reprogramming of breast cancer subtypes in 3D cultures and implications for sensitivity to targeted therapy
     Esmee Koedoot, Liesanne Wolters, Marcel Smid, Peter Stoilov, Gerhard A. Burger, Bram Herpers, Kuan Yan, Leo Price, John W.M. Martens, Sylvia E. Le Dévédec et al. · 2021 · Scientific Reports